Differences in the Measurement of Functional Residual Capacity Between Body Plethysmographs of Two Manufacturers.
body plethysmography
functional residual capacity
lung function
static lung volumes
Journal
International journal of chronic obstructive pulmonary disease
ISSN: 1178-2005
Titre abrégé: Int J Chron Obstruct Pulmon Dis
Pays: New Zealand
ID NLM: 101273481
Informations de publication
Date de publication:
2022
2022
Historique:
received:
21
02
2022
accepted:
09
06
2022
entrez:
1
7
2022
pubmed:
2
7
2022
medline:
6
7
2022
Statut:
epublish
Résumé
Body plethysmography is a fundamental method for the assessment of static lung volumes. Although equipment is provided by several manufacturers, there are no established cross-vendor tools for quality control. In the process of quality control and analysis of data on hyperinflation from the large COPD cohort COSYCONET, hints appeared that plethysmographs of different vendors might yield different values for static lung volumes. Functional residual capacity (FRC) differed about 0.67 litres between plethysmographs of the manufacturer Vyaire and Ganshorn. Absolute differences of residual lung volume (RV) and total lung capacity (TLC) were similar. It appears undeniable that differences of this magnitude have an impact on clinical interpretation. Thus, device harmonization seems to be required.
Identifiants
pubmed: 35774592
doi: 10.2147/COPD.S363493
pii: 363493
pmc: PMC9239195
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1477-1482Informations de copyright
© 2022 Alter et al.
Déclaration de conflit d'intérêts
Peter Alter declares no relevant competing interests. Jan Orszag declares no relevant competing interests. Emiel F. M. Wouters declares no relevant competing interests. Claus F. Vogelmeier declares grants or contracts to his institution from the German Ministry of Education and Science (BMBF), AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols, and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Menarini, Novartis, and Nuvaira, MedUpdate, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Aerogen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, GlaxoSmithKline, Menarini, and Novartis, all of which are outside the scope of the submitted work. Rudolf A. Jörres declares no relevant competing interests.
Références
Int J Chron Obstruct Pulmon Dis. 2018 Aug 23;13:2551-2555
pubmed: 30197511
Eur Respir J Suppl. 1993 Mar;16:5-40
pubmed: 8499054
Eur Respir J. 2012 Dec;40(6):1324-43
pubmed: 22743675
Respir Med. 2016 May;114:27-37
pubmed: 27109808
Eur Respir J. 2017 Mar 6;49(3):
pubmed: 28182564
Respirology. 2013 Jan;18(1):170-8
pubmed: 23279785
Am J Respir Crit Care Med. 2009 Dec 1;180(11):1083-91
pubmed: 19745204
ERJ Open Res. 2020 Jul 27;6(3):
pubmed: 32743009
Respir Med. 2011 Jul;105(7):959-71
pubmed: 21356587